Deutsche Bank resumes Ipsen stock with buy rating citing Somatuline

Published 04/06/2025, 08:34
Deutsche Bank resumes Ipsen stock with buy rating citing Somatuline

On Wednesday, Deutsche Bank (ETR:DBKGn) analysts resumed coverage of Ipsen (EPA:IPN) SA stock with a Buy rating, setting a price target of €122.00. The analysts highlighted the continued strong performance of Ipsen’s Somatuline, which has outperformed company consensus for the last four quarters.

The analysts attributed Somatuline’s success to the challenges faced by generic competitors in maintaining a steady supply. They noted that even if generic supply resumes, the impact on Somatuline sales is not expected to be immediate.

Deutsche Bank also pointed out the increasing investor interest in Ipsen’s long-acting neurotoxin (LANT). The analysts expressed a positive risk-reward view on the likelihood of proof-of-concept (PoC) success for this product.

The analysts’ coverage resumption reflects confidence in Ipsen’s strategic positioning and product pipeline, particularly in the face of competitive pressures in the pharmaceutical market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.